In the US, New Jersey is a life science powerhouse. It’s home to some of the most influential pharma manufacturers in the world. And today, I want to share with you some of the latest developments coming from this hub.
First off, keep your eye on Dr Reddy’s. Most recently, the company extended its strategic partnership with Gland Pharma to launch Ertapenem, which is the generic version of INVANZ.
Before that, in April, Dr Reddy’s also launched a generic for Albendazole tablets, used for the treatment of a variety of parasitic worm infestations. Considering the demand that the Albenza brand and generics received from the US, I expect this to be popular.
Moving on, Wockhard are on the rise – boosted by the growing US markets for scarlet fever and dexamethasone, whilst also producing COVID-19 vaccines in the fight against the global pandemic.
The same goes for Teva Pharmaceuticals – the world’s largest generics maker – which is set for growth following the launch of two new drugs: Huntington’s disease treatment, Austedo; and migraine product, Ajovy.
Finally, there’s Catalent. A company that’s always up to something big and exciting. Recently, Catalent entered a global innovation partnership with HBC to develop a delayed-release formulation of HBC’s OmeGo fish oil.
There’s so much more exciting news coming from New Jersey and the US. Share your news and tell me what I’ve missed by emailing me at Elle.Twomey@lifesci-cm.com.
Go to my profile page for more about myself and my content.
What are organisations doing to improve diversity in clinical trials? Click to find out what a panel of CRO leaders had to say in our latest live webinar. Now available as a podcast.
In this episode of CM Conversations, our guest share his tips on hitting the ground running and building a team remotely, as well as the importance of investing in relationships. In his words, you should always be visible and available.
In the US, New Jersey is a life science powerhouse. It’s home to some of the most influential pharma manufacturers in the world. Click to find out some of the latest developments coming from this area.